Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Bivalent RSV+HMPV Vaccine in Adults >= 60 Years
NCT07810010Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (4 cohorts), sponsored by Sanofi. Primary endpoints: Occurrence of the first episode of RSV-LRTD (Lower Respiratory Tract Disease) and Occurrence of the first episode of HMPV-LRTD (Lower Respiratory Tract Disease). Started Sep 2026; status: recruiting.
02
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT07810010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810010.